Given the metabolic reprogramming changes occurring in CRC, and the unknown changes occurring in LARC in response to NAT, this review aims to assess the literature for metabolomic, proteomic, and transcriptomic studies on patients receiving NAT for LARC to identify the mechanisms of reprogramming metabolic pathways in response to NAT. The gene discussed is BRD2; the disease is colorectal carcinoma.